Products are for professional/laboratory use only.
Among the studies published, four studies on the Idylla™ GeneFusion Assay highlighted the strengths of Idylla™ testing including high accuracy, ease-of-use and rapid time-to-results.
Products are for professional/laboratory use only
Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1 and RET fusions & MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections from patients with NSCLC.
Products are for professional/laboratory use only.
New Study Led by Memorial Sloan Kettering Cancer Center (NY, US)
This study shows that Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods:
Products are for professional/laboratory use only.
Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes
Products are for professional/laboratory use only.
Biocartis is pleased to announce the launch of the Idylla™ ctEGFR Mutation Assay (RUO1). This assay is the liquid biopsy version of the solid biopsy Idylla™ EGFR Mutation Test (CE-IVD).
Products are for professional/laboratory use only.
Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the CE-IVD marking of its fully automated Idylla™ MSI Test which allows for fast and accurate information on a patient’s MSI status directly from a single sample of FFPE[1] colorectal cancer tumor tissue. This CE-IVD launch is a key addition to Biocartis’ colorectal cancer (CRC) Idylla™ test menu as MSI detection is currently recommended for all patients with CRC[2].
Products are for professional/laboratory use only.
On the 3rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.
Products are for professional/laboratory use only.
Press Release: Mechelen, Belgium, 27 June 2018
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
